Tandem Diabetes Care

Tandem Diabetes Care has secured $265 million in convertible senior notes due 2032, with an option for an additional $40 million. This funding will accelerate the company’s strategic initiatives, including advancing its diabetes technology, expanding global market reach, and investing in research and development. The offering reflects strong investor confidence in Tandem’s growth trajectory and its innovative insulin delivery systems.